Cardiovascular risk following metformin treatment in patients with type 2 diabetes mellitus: Results from meta-analysis.,Diabetes Research and Clinical Practice

当前位置： X-MOL 学术 › Diabetes Res. Clin. Pract. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Cardiovascular risk following metformin treatment in patients with type 2 diabetes mellitus: Results from meta-analysis.
Diabetes Research and Clinical Practice ( IF 6.1 ) Pub Date : 2020-01-03 , DOI: 10.1016/j.diabres.2020.108001
Kui Zhang ₁ , Wenxing Yang ₂ , Hao Dai ₁ , Zhenhua Deng ₁

Affiliation

AIM Pharmacologic therapy for T2DM has proven benefits in terms of reducing elevated blood glucose levels and reducing microvascular complications. However, the impact of metformin on adverse cardiovascular outcomes and cardiovascular mortality is less clear. We carried out this meta-analysis on all published studies to estimate the overall cardiovascular risk following metformin treatment in patients with T2DM. METHODS We searched the PubMed, Embase and CNKI (China National Knowledge Infrastructure) databases for all articles. The odds ratio (OR) corresponding to the 95% confidence interval (95% CI) was used to assess the cardiovascular risk following metformin treatment in patients with T2DM. The statistical heterogeneity among studies was assessed with the Q-test and I2 statistics. RESULTS We collected 16 studies including 25 comparisons with 1,160,254 patients of type 2 diabetes mellitus and 701,843 patients of T2DM following metformin treatment. Our results found statistical evidence of significantly decreased cardiovascular risk to be associated with following treatment with metformin in patients with type 2 diabetes mellitus (OR = 0.57, 95% CI = 0.48-0.68) (shown in Table 1 and Fig. 2), both with the mortality (OR = 0.44, 95% CI = 0.34-0.57) and incidence (OR = 0.73, 95% CI = 0.59-0.90). CONCLUSIONS Our meta-analysis indicated that following metformin treatment in patients with T2DM was associated with decreased cardiovascular risk, both with the mortality and incidence. However, the heterogeneity among studies may potentially affect the final results.

更新日期：2020-01-04

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11